BIOMAT Database Logo BIOMAT Database Logo

Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy. 2001

F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Department of Ophthalmology, University of Udine, Udine, Italy. Bandello@dsc.uniud.it

OBJECTIVE We misled to verify whether a panretinal photocoagulation (PRP) performed using low levels of ARGON laser energy (light PRP) has the same efficacy as a PRP performed in a conventional fashion using argon green wavelengths (classic PRP) in eyes with high-risk proliferative diabetic retinopathy (HRPDR). Furthermore, we misled to compare the session number performed and the side effects produced by the two techniques. METHODS Sixty-five eyes with HRPDR of 50 consecutive patients were enrolled in a prospective randomized controlled trial. In eyes selected for light PRP, a very light biomicroscopic effect on the retina was obtained for each spot. In eyes assigned to classic PRP, each spot produced a white-yellow biomicroscopic effect. Mean follow-up was 22.4 months +/- 9.7 in the light PRP and 21.6 months +/- 9.3 in the classic PRP group (p = 0.727). RESULTS The initial mean logMAR visual acuity (VA) in the light PRP group was 0.12 +/- 0.13 and in the classic PRP group 0.14 +/- 0.15 (p = 0.493). The final mean VA in the former was 0.18 +/- 0.25, and in the latter 0.27 +/- 0.30 (p = 0.231). Median power was 235mW (100-540mW) for light and 420mW (200-950mW) for classic PRP (p < 0.001). Regression of HRPDR at the end of the follow-up was obtained in 30/31 eyes (97%) treated with classic PRP and in 31/34 eyes (91%) treated with light PRP (p = 0.615). The total mean session number was 7.4 +/- 2.4 for light and 9.9 +/- 2.2 for the classic PRP group (p < 0.001). Complications were more frequent in the classic PRP group. CONCLUSIONS The efficacy of Light PRP is similar to that of classic Light PRP in eyes with HRPDR. Light PRP is associated with fewer complications and allows the reduction of the number of treatment sessions.

UI MeSH Term Description Entries
D008028 Light Coagulation The coagulation of tissue by an intense beam of light, including laser (LASER COAGULATION). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, hemorrhages, and malignant and benign neoplasms. (Dictionary of Visual Science, 3d ed) Photocoagulation,Coagulation, Light,Coagulations, Light,Light Coagulations,Photocoagulations
D008269 Macular Edema Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90) Central Retinal Edema, Cystoid,Cystoid Macular Edema,Macular Edema, Cystoid,Cystoid Macular Dystrophy,Cystoid Macular Edema, Postoperative,Irvine-Gass Syndrome,Macular Dystrophy, Dominant Cystoid,Edema, Cystoid Macular,Edema, Macular,Irvine Gass Syndrome,Syndrome, Irvine-Gass
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Panretinal Photocoagulation Plus Intravitreal Bevacizumab Versus Panretinal Photocoagulation Alone for Proliferative Diabetic Retinopathy.
December 2018, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Panretinal photocoagulation for proliferative diabetic retinopathy.
October 2011, The New England journal of medicine,
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Panretinal photocoagulation for proliferative diabetic retinopathy.
April 2012, American journal of ophthalmology,
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.
January 2016, International journal of ophthalmology,
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
May 2018, Ophthalmology,
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
October 2016, Retina (Philadelphia, Pa.),
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy.
January 2012, Journal of Ayub Medical College, Abbottabad : JAMC,
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Incremental panretinal photocoagulation. Results in treating proliferative diabetic retinopathy.
January 1983, Retina (Philadelphia, Pa.),
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Pattern Scanning Laser Panretinal Photocoagulation in Proliferative Diabetic Retinopathy.
January 2017, Ophthalmology. Retina,
F Bandello, and R Brancato, and U Menchini, and G Virgili, and P Lanzetta, and E Ferrari, and C Incorvaia
Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
September 2016, Ophthalmology,
Copied contents to your clipboard!